MedTrace Logo

Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study

NCT06202417 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 520

Last updated 2024-01-11

No results posted yet for this study

Summary

Fruquintinib is an oral tyrosine kinase inhibitor (TKI), which improves progression-free survival (PFS) and overall survival (OS) in patients with refractory metastatic colorectal cancer (mCRC). Here, we explore the real-world treatment patterns of fruquintinib in the third- or late-line setting for mCRC in six centers in China.

Conditions

Interventions

DRUG

Fruquintinib

an oral tyrosine kinase inhibitor (TKI)

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Jianmin Xu · Fudan University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2022-06-30
Completion
2023-12-25

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06202417 on ClinicalTrials.gov